levothyroxine sodium

FDA Drug Profile — LEVOTHYROXINE SODIUM, Levothyroxine Sodium, levothyroxine sodium, EUTHYROX, Unithroid

Drug Details

Generic Name
levothyroxine sodium
Brand Names
LEVOTHYROXINE SODIUM, Levothyroxine Sodium, levothyroxine sodium, EUTHYROX, Unithroid, Tirosint, LEVOXYL
Application Number
ANDA215259
Sponsor
Camber Pharmaceuticals, Inc.
NDC Codes
50
Dosage Forms
TABLET, INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION, CAPSULE
Routes
ORAL, INTRAVENOUS
Active Ingredients
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS

Indications and Usage

1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium may induce hyperthyroidism [see Warnings and Precautions (5.1) ]. Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets are a L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1) Limitations of Use: Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis